Previous 10 | Next 10 |
2023-07-18 08:50:04 ET Novartis' ( NYSE: NVS ) board said that it would initiate a buyback of up to $15B worth of shares by the end of 2025 as the Swiss drugmaker also boosted its 2023 sales guidance. Both items were revealed during Novartis' ( NVS ) Q2 financial results in ...
2023-07-18 03:27:58 ET Novartis press release ( NYSE: NVS ): Q2 Non-GAAP EPS of $1.83 beats by $0.07 . Revenue of $13.62 billion (+6.6% Y/Y) beats by $410 million . Innovative Medicines net sales was $11.2 billion (+7%, +9% cc), with volume contributing 15...
2023-07-17 05:41:13 ET Stock futures were largely unchanged during Monday's premarket action ahead of a busy Q2 earnings season with releases from some of the world's most prominent companies , such as EV giant Tesla ( TSLA ), Goldman Sachs ( GS ), ...
2023-07-14 15:00:24 ET Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar ...
2023-07-13 09:29:04 ET TG Therapeutics ( NASDAQ: TGTX ), the developer of FDA-approved multiple sclerosis therapy Briumvi, lost ~10% pre-market Thursday after Genentech, a unit of Roche ( OTCQX:RHHBY ) ( OTCQX:RHHBF ), said Thursday that its product Ocrevus reached its m...
2023-07-12 02:46:43 ET Summary Shares of precision oncology concern Erasca have tumbled 80% from their IPO pricing in June 2021 as early-stage clinical data from its programs have failed to impress. To get it closer to commercialization, ERAS in-licensed pan-RAF inhibitor naporafe...
2023-07-11 19:31:22 ET Summary Aclaris Therapeutics, Inc. results from a phase 2b study using zunsemetinib for the treatment of patients with rheumatoid arthritis are expected to be released by Q4 of 2023. The global rheumatoid arthritis market is expected to reach $33.3 billion b...
2023-07-10 19:13:34 ET Summary Gilead has purchased $10.9 million in shares of Allovir, a biotech company specializing in cell therapy and organ transplant, giving it a 15% ownership of the company. Allovir's lead product, posoleucel, is in Phase III clinical trials and targets si...
2023-07-10 13:40:24 ET AbbVie ( NYSE: ABBV ) inched lower for the third straight session on Monday after Express Scripts, the pharmacy benefits management (PBM) unit of Cigna ( NYSE: CI ), pledged to cover three new biosimilars targeted at the company’s blockbuster ar...
2023-07-10 13:00:09 ET Novartis ( NYSE: NVS ) said it has received expanded approval for its cholesterol-fighting drug Leqvio from US regulators. The FDA has approved Leqvio, also known as inclisiran, for the treatment of high LDL cholesterol in adults who are at increased risk ...
News, Short Squeeze, Breakout and More Instantly...
2024-07-19 04:04:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-18 16:45:16 ET Image source: The Motley Fool. Novartis Ag (NYSE: NVS) Q2 2024 Earnings Call Jul 18, 2024 , 8:00 a.m. ET Operator Continue reading For further details see: Novartis Ag (NVS) Q2 2024 Earnings Call Transcript
2024-07-18 14:15:34 ET By most standards shares of drugmaker Novartis (NYSE: NVS) should be higher following this morning's release of its second-quarter results. The drugmaker's top and bottom lines were both better than expected, and up from year-earlier comparisons. And profit gu...